Table 3.

Effectiveness of three consecutive monthly doses of Credelio Plus^® and afoxolaner + milbemycin oxime based on laboratory counts and speciation of natural flea infestations for dog, cat and human flea species on client owned dogs in European field study

Study day	Treatment group	C. felis		C. canis		P. irritans
		AM flea count	% Effectiveness	AM flea count	% Effectiveness	AM flea count	% Effectiveness
0	Credelio Plus®	18.5	–	11.4	–	6.6	–
	Afoxolaner + Milbemycin oxime	10.4	–	20.7	–	10.5	–
14 ± 2	Credelio Plus®	0.25	98.6	0	100	0	100
	Afoxolaner + Milbemycin oxime	0.09	99.1	0.09	99.6	0.06	99.4
28 ± 2	Credelio Plus®	0.07	99.6	0	100	0	100
	Afoxolaner + Milbemycin oxime	0.63	94.0	0	100	0	100
56 ± 2	Credelio Plus®	0	100	0	100	0	100
	Afoxolaner + Milbemycin oxime	0.10	99.0	0	100	0	100
84 ± 2	Credelio Plus®	0	100	0	100	0–0	100
	Afoxolaner + Milbemycin oxime	0	100	0	100	0–0	100

Before treatment administration on Day 0, the number of dogs in the Credelio Plus^® and afoxolaner + milbemycin oxime groups infested with each species was 58 and 32 for C. felis, 29 and 11 for C. canis and 18 and 10 for P. irritans, respectively